Johnson & Johnson PE ratio JNJ

Share price divided by earnings per share over the last twelve months, since 2010.

Today, Oct 23, 2026: 40.0×
10-year median: 24.3×
Against its 10-year history: 90th; percentile: 0 is its lowest day, 100 its highest
10-year range: 9.6× to 346×
Peer median: 41.1×

Johnson & Johnson's PE ratio is 40.0× as of Oct 23, 2026: a share price of $263.81 against $6.60 of earnings per share over the last twelve months.

That is above its ten-year median of 24.3×, higher than on 90% of days in the last ten years.

Over that time it ranged from 9.6× in Jun 2024 to 346× in Jul 2018.

The median for 7 large drugmakers of a similar size is 41.1×.

PE ratio over time

median 24.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	40.0×	19.7×	40.0×
2025	20.0×	16.7×	28.8×
2024	24.0×	9.6×	27.3×
2023	11.6×	10.9×	36.5×
2022	24.6×	20.9×	26.0×
2021	25.6×	23.8×	30.4×
2020	24.7×	21.3×	28.9×
2019	27.8×	21.2×	273×
2018	255×	22.5×	346×
2017	24.3×	20.1×	24.7×
2016	20.4×	18.5×	23.4×
2015	19.6×	16.0×	19.8×
2014	17.4×	17.3×	21.1×
2013	20.5×	19.2×	25.2×
2012	22.9×	15.8×	23.3×
2011	16.0×	12.3×	16.1×
2010	12.7×	11.9×	13.4×

Against its peers

Companies in Drug Manufacturers - General nearest Johnson & Johnson's size, closest first, today.

Company	PE ratio
JNJJohnson & Johnson	40.0×
ABBVAbbVie	80.7×
MRKMerck	116×
LLYEli Lilly and	42.7×
AMGNAmgen	27.3×
GILDGilead Sciences	n/m
PFEPfizer	39.5×
BMYBristol-Myers Squibb	13.5×
Peer median	41.1×

Where Johnson & Johnson ranks

#28of 41Large drugmakers with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Johnson & Johnson

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.